Rezolute, Inc. (RZLT), a late-stage biopharmaceutical company focused on rare diseases, provided an update on its Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital hyperinsulinism or HI.
The open-label arm of the study, which enrolled 8 infant participants aged 3 months to 1 year, has been reviewed by an independent Data Monitoring Committee or DMC.
The review confirmed that ersodetug was well-tolerated and reached the target drug concentrations at the tested doses of 5 and 10 mg/kg.
Based on these findings, the DMC has approved the enrollment of infants into the double-blind portion of the study.
The trial is on track for enrollment completion in Q2 2025, pending recommendations from an upcoming interim analysis or IA, which will assess the sample size adequacy for the primary endpoint.
Topline results from the study are expected in Q4 2025.
Ersodetug, a monoclonal antibody targeting insulin receptor over-activation, shows promise as a universal treatment for hypoglycemia due to congenital or acquired HI, which is currently underserved by available therapies.
RZLT closed Tuesday's (FEB.04 2025) trading at $5.50 up by 4.96%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.